Published in J Clin Oncol on December 21, 2009
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
Smoldering multiple myeloma. Blood (2015) 1.03
Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J (2012) 1.01
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia (2012) 0.99
Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. Rev Bras Hematol Hemoter (2013) 0.98
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol (2010) 0.95
Haematological cancer: Treatment of smoldering multiple myeloma. Nat Rev Clin Oncol (2013) 0.95
Imaging of multiple myeloma: Current concepts. World J Orthop (2014) 0.87
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol (2010) 0.85
Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am (2012) 0.80
Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy. BMC Clin Pathol (2012) 0.80
Smoldering multiple myeloma. Biomed Res Int (2015) 0.75
FDG-PET imaging in hematological malignancies. Blood Rev (2016) 0.75
Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials. PLoS One (2014) 0.75
The effect of the suppressed levels of uninvolved immunoglobulins on the prognosis of symptomatic multiple myeloma. Turk J Haematol (2016) 0.75
Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget (2016) 0.75
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood (2000) 3.60
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med (1996) 3.41
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia (2009) 2.28
Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 2.04
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol (2003) 1.87
Smoldering multiple myeloma. N Engl J Med (1980) 1.77
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol (2002) 1.76
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res (2002) 1.57
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol (2006) 1.44
Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica (2004) 1.42
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer (2008) 1.39
Localized and indolent myeloma. Blood (1980) 1.33
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. Eur J Haematol (1993) 1.32
Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc (2007) 1.27
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood (2004) 1.26
Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol (2003) 1.24
Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol (2005) 1.17
Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol (1994) 1.14
Prognostic features of asymptomatic multiple myeloma. Br J Haematol (1997) 1.13
Risk of disease progression in asymptomatic multiple myeloma. Am J Med (1993) 1.12
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer (2000) 1.09
Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol (1995) 1.08
Complications of multiple myeloma. Hematol Oncol Clin North Am (2007) 1.03
Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol (1988) 1.01
Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol (1995) 1.01
Prognosis of asymptomatic multiple myeloma. Arch Intern Med (1988) 1.01
Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM). Am J Hematol (1995) 0.99
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol (2002) 0.97
Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol (1999) 0.97
Anti-myeloma activity of pamidronate in vivo. Br J Haematol (1998) 0.91
Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II. Eur J Haematol (1991) 0.91
First thalidomide clinical trial in multiple myeloma: a decade. Blood (2008) 0.90
A prognostic index for multiple myeloma. Br J Cancer (1996) 0.90
Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr Treat Options Oncol (2006) 0.89
Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. Radiology (1996) 0.87
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma (2003) 0.87
Transient response of myeloma clone to pamidronate therapy. Haematologica (1999) 0.77
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol (2002) 3.45
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Multiple myeloma: diagnosis and treatment. Mayo Clin Proc (2005) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol (2002) 2.55
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Current therapy for multiple myeloma. Mayo Clin Proc (2002) 2.47
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc (2004) 2.43
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
The high cost of cancer drugs and what we can do about it. Mayo Clin Proc (2012) 2.39
Unusual myelomas: a review of IgD and IgE variants. Oncology (Williston Park) (2013) 2.35
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer (2004) 2.31
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol (2011) 2.27
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) (2011) 2.21
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood (2003) 2.12
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol (2008) 2.09
Emerging therapies for multiple myeloma. Oncology (Williston Park) (2009) 2.08
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Empiricism and rationalism in medicine: can 2 competing philosophies coexist to improve the quality of medical care? Mayo Clin Proc (2013) 2.07
Screening panels for detection of monoclonal gammopathies. Clin Chem (2009) 2.05
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood (2006) 1.98